Patenting antibodies: a personal take on maturing technology
14 Jul 2025
As the tools for generating and characterising antibodies become more sophisticated and widely available, patent offices are re-evaluating how they assess key legal requirements...
READ MORE
Revised Indian Biodiversity Law aims to boost bioresource-dependent sectors
30 Oct 2023
The new Indian Biodiversity Law - a significant step towards encouraging science and innovation in the related sectors, and achieving the ambitious goal of...
READ MORE
Maximising Patent Term Extension in Korea: strategies and recommendations
24 Jul 2023
Patent Term Extension (PTE) in Korea provides an opportunity to extend the term of a patent based on regulatory approval or Marketing Authorisation (MA)...
READ MORE
A good night for Neurim Pharmaceuticals - Assistant Commissioner Luiten as an agent for controlling the release of an examined patent application
03 Aug 2022
Neurim Pharmaceuticals was unsuccessful in overcoming the examiner’s repeated objections to its New Zealand patent application, but the application will be accepted subject to...
READ MORE
Australia’s Full Federal Court diagnoses an outcome, not a product
05 May 2022
Examining a recent court decision; the latest in a long running, multi-jurisdictional dispute between the parties concerning the validity and infringement of claims to...
READ MORE
Recent reform on Brazilian pharmaceutical patents showing results
11 Apr 2022
The Brazilian legislature revoke controversial article (Article 229-C) in the Brazilian IP Law......
READ MORE
BECOME A MEMBER OF FICPI
FICPI is the only international NGO whose membership consists exclusively of IP attorneys in private practice. As a result, the FICPI community is driven by a shared interest to promote solutions and advocacy for private IP practitioners.